Metabolomics in Dyslipidemia

Chen, Hua; Miao, Hua; Feng, Ya-Long; Zhao, Ying-Yong; Lin, Rui‐Chao

doi:10.1016/b978-0-12-801401-1.00004-9

Cited by 72 publications

(37 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past 10 years, lipidomics has emerged as a new field in systems biology and has increased interest in disease diagnosis and biomarker discovery (obesity, diabetes, cardiovascular disease, Alzheimer's disease, pancreatic cancer, etc. ), pharmaceutical discovery and development, human food and nutrition research [49][50][51][52][53][54][55]. This powerful approach can reveal unique metabolic characteristics of normal, pathologic, or treatment-specific events.…”

Section: Lipidomicsmentioning

confidence: 99%

Lipidomics

Zhao

Vaziri

Lin

2015

Advances in Clinical Chemistry

Self Cite

View full text Add to dashboard Cite

Section: Lipidomicsmentioning

confidence: 99%

Lipidomics

Zhao

Vaziri

Lin

2015

Advances in Clinical Chemistry

Self Cite

View full text Add to dashboard Cite

“…Due to the complexity and various factorial interactions of diseases, the situation seems difficult in the field of clinical chemistry for which multiplexed targeted approaches provide the clinician with information on a limited number of metabolites by using MS/MS analysis performed on triple quadruple MS. Furthermore, recent improvements in UPLC-QTOF/MS/MS E have improved the efficacy of global approaches by facilitating the identification of metabolites of interest thanks to high-resolution and accurate mass measurements, which Q-TOF/MS/MS E can simultaneously acquire MS and MS/MS (MS E ) data of all the metabolites through alternating between high and low collision energies during a single chromatographic run [112][113][114][115][116][117][118][119][120].…”

Section: Concluding Remarks and Perspectivesmentioning

confidence: 99%

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

Zhao

Cheng

Vaziri

et al. 2014

Clinical Biochemistry

Self Cite

118

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oObjectives: Metabonomics is a powerful and promising analytic tool that allows assessment of global lowmolecular-weight metabolites in biological systems. It has a great potential for identifying useful biomarkers for early diagnosis, prognosis and assessment of therapeutic interventions in clinical practice. The aim of this review is to provide a brief summary of the recent advances in UPLC-based metabonomic approach for biomarker discovery in a variety of diseases, and to discuss their significance in clinical chemistry.Design and methods: All the available information on UPLC-based metabonomic applications for discovering biomarkers of diseases were collected via a library and electronic search (using Web of Science, Pubmed, ScienceDirect, Springer, Google Scholar, etc.).Results: Metabonomics has been used in clinical chemistry to identify and evaluate potential biomarkers and therapeutic targets in various diseases affecting the liver (hepatocarcinoma and liver cirrhosis), lung (lung cancer and pneumonia), gastrointestinal tract (colorectal cancer) and urogenital tract (prostate cancer, ovarian cancer and chronic kidney disease), as well as metabolic diseases (diabetes) and neuropsychiatric disorders (Alzheimer's disease and schizophrenia), etc.Conclusions: The information provided highlights the potential value of determination of endogenous lowmolecular-weight metabolites and the advantages and potential drawbacks of the application of UPLC-based metabonomics in clinical setting.

show abstract

“…Hyperlipidemia comprises a group of plasma lipoprotein abnormalities, including increased triglycerides (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL), and reduced high density lipoprotein cholesterol (HDL) concentrations (Chen et al, 2014b). Hyperlipidemia is a dominant risk factor that contributes to cardiovascular disease (Abliz et al, 2014; Kim et al, 2015), and its development has become a difficult public health problem (Chen et al, 2014b). At present, drug therapy is the preferred treatment for hyperlipidemia.…”

Section: Introductionmentioning

confidence: 99%

Modulation of the Gut Microbiota by Krill Oil in Mice Fed a High-Sugar High-Fat Diet

Sun

et al. 2017

Front. Microbiol.

View full text Add to dashboard Cite

Multiple lines of evidence suggest that the gut microbiota plays vital roles in metabolic diseases such as hyperlipidemia. Previous studies have confirmed that krill oil can alleviate hyperlipidemia, but the underlying mechanism remains unclear. To discern whether krill oil changes the structure of the gut microbiota during the hyperlipidemia treatment, 72 mice were acclimatized with a standard chow diet for 2 weeks and then randomly allocated to receive a standard chow diet (control group, n = 12) or a high-sugar-high-fat (HSHF) diet supplemented with a low (100 μg/g·d, HSHF+LD group, n = 12), moderate (200 μg/g·d, HSHF+MD group, n = 12) or high dosage of krill oil (600 μg/g·d, HSHF+HD group, n = 12), simvastatin (HSHF+S group, n = 12) or saline (HSHF group, n = 12) continuously for 12 weeks. The resulting weight gains were attenuated, the liver index and the low-density lipoprotein, total cholesterol and triglyceride concentrations showed a stepwise reduction in the treated groups compared with those of the control group. A dose-dependent modulation of the gut microbiota was observed after treatment with krill oil. Low- and moderate- doses of krill oil increased the similarity between the composition of the HSHF diet-induced gut microbiota and that of the control, whereas the mice fed the high-dose exhibited a unique gut microbiota structure that was different from that of the control and HSHF groups. Sixty-five key operational taxonomic units (OTUs) that responded to the krill oil treatment were identified using redundancy analysis, of which 26 OTUs were increased and 39 OTUs were decreased compared with those of the HSHF group. In conclusion, the results obtained in this study suggest that the structural alterations in the gut microbiota induced by krill oil treatment were dose-dependent and associated with the alleviation of hyperlipidemia. Additionally, the high-dose krill oil treatment showed combined effects on the alleviation of hyperlipidemia and obesity.

show abstract

Metabolomics in Dyslipidemia

Cited by 72 publications

References 60 publications

Lipidomics

Lipidomics

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

Modulation of the Gut Microbiota by Krill Oil in Mice Fed a High-Sugar High-Fat Diet

Contact Info

Product

Resources

About